Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07774533 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07774533 · ClinicalTrials.gov record · last posted 2026-08-19

68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma

Name: 68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma — clinical trial record (NCT07774533)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhaseEarly Phase 1

SponsorPeking University First Hospital

Started2026-04-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET/CT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.

Trial Details

NCT Number	NCT07774533
Lead Sponsor	Peking University First Hospital
Conditions	Osteosarcoma, Osteosarcoma, Recurrent, Refractory
Enrollment	16 participants
Start Date	2026-04-01
Primary Completion	2026-08-05 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-19